Top 50 Cell Line Development in Asia

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

ProFuse Technology specializes in muscle cell differentiation, fusion, and maturation through proprietary supplements and immortalized bovine muscle cell lines, enhancing the efficiency of cultivated meat production. Their solutions aim to increase yield, reduce production costs, and accelerate production cycles for life science and cultivated meat companies.

Solaris Bio develops serum-free culture media and related solutions for cell manufacturing in regenerative medicine, utilizing proprietary AI technology to enhance the safety and efficacy of cell products while reducing costs. The startup addresses the need for chemically defined and animal origin-free media formulations that optimize cell growth and differentiation for various therapeutic applications.

Cellivate provides proprietary cell-based technologies that enhance the growth of animal cells for applications in cultivated meat, skincare, and leather production. By offering cost-effective solutions that integrate into existing workflows, Cellivate addresses the need for sustainable alternatives to traditional animal-derived products.

iCamuno Biotherapeutics develops a cell therapy drug using induced pluripotent stem cells (iPSCs) and gene editing technologies to create effective and affordable treatments for cancer patients. The company focuses on somatic cell reprogramming and stem cell differentiation to provide universal access to safe cellular therapies that meet unmet clinical needs.

uBriGene provides custom cell and gene therapy services, including development, manufacturing, and quality control for advanced therapy medicinal products (ATMPs) such as plasmids, mRNA-LNPs, and viral vectors. The company accelerates the transition from research to clinical application, ensuring regulatory compliance and product integrity throughout the process.

Gracell Biotechnologies develops CAR-T cell therapies using its FasTCAR platform for next-day manufacturing of younger, less exhausted CAR-T cells, and its TruUCART platform for off-the-shelf allogeneic therapies. The company aims to provide effective treatment options for patients with cancer and autoimmune diseases, addressing the limitations of conventional CAR-T therapies.

East Ocean Bio Private Limited develops allogeneic chimeric antigen receptor (CAR)-NK cell therapies using synthetic biology and non-viral cell engineering to enhance the tumor-targeting capabilities of natural killer cells. This technology aims to provide effective treatment options for challenging cancers, including solid tumors, while ensuring early and affordable access to curative therapies in India and beyond.

Optieum Biotechnologies develops antibody-based therapies utilizing the Eumbody System to create optimized single-chain variable fragments (scFvs) for generating CAR-T cells with enhanced anti-tumor efficacy. Their technology addresses the challenge of treating refractory cancers by improving the proliferation and longevity of CAR-T cells, leading to better patient outcomes and reduced side effects.

Genexis Biotech produces animal‑free recombinant proteins, growth factors, and serum‑free media using precision‑fermentation of engineered microbes, delivering >95 % purity and GMP‑compatible quality. The company offers custom protein design, strain and metabolic engineering, and scale‑up consulting to enable consistent cell growth for biotech, cellular‑agriculture, regenerative‑medicine, and cosmetics applications.

Immuneel Therapeutics is developing Chimeric Antigen Receptor T cell (CAR-T) therapies to provide affordable and accessible cell and gene treatments for cancer patients in India. The startup addresses the lack of advanced cancer therapies in the country, aiming to improve patient outcomes through personalized immunotherapy.

Integriculture develops a large-scale cellular cultivation technology called the CulNet System, which produces sustainable food products to enhance food security and public health. By providing a marketplace and starter kits for researchers, the company addresses the challenges of traditional agriculture and resource scarcity.

Eyestem develops scalable cell replacement therapies using induced pluripotent stem cells to create retinal pigment epithelium (RPE) cells for treating Dry Age-related Macular Degeneration (AMD), a leading cause of blindness in individuals over 60. The company aims to democratize access to these therapies by embedding efficient manufacturing and quality processes, significantly reducing the time to market.

This startup specializes in drug discovery by developing botanical medicines and therapeutics from natural compounds, utilizing cannabis molecular analysis and pre-clinical trials. It enables researchers to evaluate the efficacy of cannabis and psilocybin extracts on various cell line models, facilitating the integration of botanical medicine into the pharmaceutical industry.

StemBio provides specialized processing, quality control, and cryopreservation for human-derived cells and tissues. They enable clinical applications of cellular therapies and tissue grafts through cGMP-compliant production of stem cells, exosomes, and gene therapies.

Cellusion develops iPS cell-derived corneal endothelial cells for the treatment of bullous keratopathy, a condition affecting over 10 million patients globally who require corneal transplants. Their technology enables the production of functional replacement cells that can be injected into the eye, bypassing the need for donor corneas and complex surgical procedures.

Mxt Biotech develops the Hydroporator®, a non-viral microfluidic platform that enables efficient delivery of plasmid DNA, mRNA, and CRISPR-Cas9 RNPs into primary cells while maintaining high cell viability and functionality. This technology addresses the limitations of viral transduction and electroporation, facilitating advancements in cancer immunotherapy and cellular engineering.

Logomix offers a Geno-Writing platform that enables precise engineering of megabase-scale genomic sequences in human cells, facilitating the creation of custom cell types with specific functions. This technology addresses the challenges of immune rejection and functional integration in cell therapies, enhancing the development of advanced regenerative medicine solutions.

Alagene offers integrated biotechnology solutions that accelerate bioproduct development from computational design and cell engineering to precision fermentation and downstream processing. They leverage high-throughput screening and advanced genetic tools to optimize biological systems, enabling efficient scale-up and commercialization for biotech and pharmaceutical companies.

Medinno develops cell therapeutics utilizing human stem cells to create targeted treatments for brain diseases such as hypoxic-ischemic encephalopathy and spinal cord injury. Their proprietary technology aims to provide effective neuro-regenerative solutions that address critical gaps in current therapeutic options for these conditions.

Sea2Cell is developing a sustainable method for producing cultivated fish meat using immortalized fish cell lines that exhibit enhanced proliferation rates in controlled tank environments. This approach addresses the overfishing crisis and the resulting threat to marine biodiversity by providing an alternative source of fish without depleting ocean resources.

MeatoLogic develops specialized cells for cellular agriculture using synthetic biology techniques to enhance cell growth and performance in meat production. This technology addresses the challenges of scalability and cost-effectiveness in the foodtech industry, enabling companies to produce cell-based products more efficiently.

The startup develops cell-related therapeutics utilizing induced pluripotent stem cells through cardiomyocyte differentiation and myocardial purification methods with small-molecule compounds. This research enables pre-clinical validation for improved regenerative medicine treatments and cell transplantation procedures.

The startup develops biopharmaceuticals by creating production cell lines and formulating drug substances and finished drugs tailored to patient needs. This approach enables the delivery of personalized medicines, addressing the lack of access to customized treatment options for patients.

The startup develops optimized parental cells for the production of stem cell exosomes, which have superior proliferation and secretion capabilities. This technology enables mass production of exosomes, providing a scalable solution for targeting incurable diseases.

The startup has developed a single-use, end-to-end autologous cell manufacturing platform that enables bedside production of life-saving therapies. This system enhances quality assurance, reduces time to market, and lowers costs, ensuring greater availability of advanced cell therapies for patients.

The startup develops a cell regenerative method utilizing regenerative T cells derived from human induced pluripotent stem (iPS) cells to create personalized immuno-cell therapies. This approach targets cancer and infectious diseases, providing tailored treatment options for patients.

This startup develops a cell precision control and diagnosis platform that automates massively parallel cellular processes within a single device. The platform enables rapid experimentation and data collection, providing researchers and healthcare providers with efficient workflows for scientific discovery.

Twogene is a contract development and manufacturing organization (CDMO) specializing in the process development and large-scale production of plasmid DNA (pDNA) and proteins for the cell and gene therapy industry. The company addresses the need for GMP-compliant manufacturing by providing fast-turnaround production capabilities, ranging from research-grade to large-scale GMP-grade batches, ensuring high-quality outputs for preclinical, clinical, and commercial applications.

The startup specializes in cell encapsulation technology that enhances the efficiency of cell mass production for engineering applications. This technology enables clients to utilize cells effectively across various domains, from research to clinical use, by providing a reliable method for handling and processing cells.

Knowledge Palette utilizes whole-genome expression profiling to extract and analyze large-scale data from stem cells, enabling precise control over cellular behavior for regenerative medicine applications. The company addresses the challenges of developing high-quality cell-based therapies for degenerative diseases, which often face variability in manufacturing and unmet medical needs.

Jimi Bio produces sustainable, cell-derived alternatives to conventional animal products using advanced mammalian cell culture technology. They offer clean-label cultivated meat and specialized bio-ingredients like deer antler cell extracts for the health and cosmetic industries.

Cell in Cells develops cell therapy products utilizing 3D stem cell technology to regenerate damaged tissues and organs. The company addresses the challenges of aging and tissue degeneration by providing solutions that aim to restore biological function and improve quality of life.

This biotechnology company develops xeno-free ancillary products for rapid T-cell expansion and activation ex vivo, alongside recombinant protein signals for cell therapeutic research. Their offerings aim to simplify and accelerate the development of cell therapeutic products.

ChemT Biotechnology is pioneering the use of small molecules to enhance the manufacturing process of immune cell therapies, achieving a 5-10x increase in yield while improving product quality. This approach addresses the high production costs and inconsistent quality that currently plague the cell and gene therapy industry.

The startup develops cellular immunotherapies that utilize in vitro activation and regulation of immune cells to treat autoimmune diseases and cancer. By reintroducing and activating regulatory cells, the company provides a targeted therapeutic approach that enhances patient outcomes in these challenging medical conditions.

Sono Biosciences develops serum-free fish cell culture media and genome-edited fish cell lines to enhance the efficiency and safety of cultured fish production. By eliminating animal-derived components, Sono addresses the high costs and ethical concerns associated with traditional fish cell culture methods, enabling scalable and sustainable aquaculture.

Myoridge specializes in the development of high-purity myocardial cells with optimized culture media, enhancing drug response rates for cardiac research and therapies. The company addresses the challenge of inefficient cell culture processes in regenerative medicine by providing tailored media solutions and comprehensive support for cell-based product development.

The startup develops a culture technology that focuses on rapidly changing cell therapies and mesenchymal stem cells for treating hypophosphatasia, a rare bone-formation deficiency in newborns, and spinal canal stenosis due to disc herniation. This technology enhances treatment efficacy for these specific medical conditions, providing targeted therapeutic solutions.

The startup develops clinical-grade human-induced pluripotent stem cells and personalized cell banking services for diabetes treatment. Their offerings enable the application of cell replacement therapies, addressing the need for effective regenerative solutions in diabetes management.

Sakura Bio is developing an off-the-shelf allogeneic T-cell therapy, Skill-T, which utilizes a proprietary manufacturing process to produce non-genetically modified T-cells with high anti-tumor cytotoxic activity and no toxicity to healthy tissue. This therapy aims to provide a safe and effective treatment option for patients with hematological malignancies and solid tumors, eliminating the risk of Graft-versus-host disease (GVHD) commonly associated with other T-cell therapies.

CytoMed Therapeutics develops allogeneic cellular immunotherapies utilizing gamma delta (γδ) T cells and natural killer (NK) cells to target a wide spectrum of solid and hematological cancers. Their proprietary technologies, including induced pluripotent stem cells (iPSCs), enable the creation of cost-effective, off-the-shelf treatments that enhance cancer cell elimination.

RadaHaim has developed a high-throughput organoid assay system that enables the automated production of organoids tailored to specific tumor and cell types for drug screening. This technology addresses the inefficiencies in the drug discovery process by providing accurate disease models that bridge the gap between basic research and clinical trials.

The startup operates a biotechnology research platform focused on developing xeno-free vascular endothelial progenitor cell therapies for diabetic foot ulcers and ischemic vascular diseases. This approach aims to provide effective treatment options for patients suffering from renal vascular and stroke-related complications.

Celaid Therapeutics develops regenerative medicine products using human hematopoietic stem cells sourced from umbilical cord and peripheral blood. The company focuses on creating next-generation cell therapies for blood cancers and genetic disorders by employing a proprietary method for the large-scale amplification of functional stem cells without animal-derived components.

Neukio develops allogenic immune cell therapies utilizing iPSC-derived CAR-NK technology to target and eliminate cancer cells. The company addresses the need for effective treatments against solid tumors by producing standardized, engineered NK cells at scale through in-house innovation and strategic partnerships.

The startup develops neural stem cell technologies for regenerative medicine aimed at treating central nervous system diseases, including spinal cord injuries and multiple sclerosis. By utilizing human neural stem cells as a cell therapy, the company provides targeted treatment options for conditions like Pelizaeus-Merzbacher disease.

China Immunotech develops gene-edited T-cell therapies using its STAR-T and enTCR-T platforms, targeting solid tumors, hematological malignancies, and viral infections. The company addresses unmet clinical needs in cancer treatment by providing advanced immune cell therapies that enhance patient outcomes.

BeiCell Therapeutics develops off-the-shelf cell therapies utilizing engineered immune cells to treat cancer and autoimmune diseases, as well as for regenerative medicine applications. This approach addresses the challenges of accessibility and customization in traditional cell therapies, providing a ready-to-use solution for patients.

This company develops biomaterials using micro and nanotechnology for applications like 3D cell culture and tissue engineering. Their bio-scaffolds, monolithic matrices, and micro-carriers facilitate advanced cell treatment and bioseparation in regenerative medicine.